FDA Approves Daraxonrasib, First RAS-Targeted Therapy for Metastatic Pancreatic Cancer

The FDA has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received prior systemic therapy or are not candidates for it. This marks the first FDA-approved RAS-targeted therapy for pancreatic cancer, demonstrating a near doubling of median overall survival in the pivotal RASolute 302 trial. This approval offers a new treatment option for a challenging cancer.